Background document potential Ebola therapies and vaccines. WHO, 3 September 2014.
Basler C.F., Miculasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., Klenks H.D., Palese P., Garcia-Sastre A. The Ebola virus VP 35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003; 77:7945-56.
Burton D.R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2002; 2:706-13.
Choi J.H., Croyle V.A. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013; 27(6):565-83. DOI: 10.1007/540259-013-0046-1..
DOI: 10.1007/540259-013-0046-1
CNN News. Available from: http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html (дата обращения 22.08.2014).http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html
CNN News. Available from: http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html (дата обращения 22.08.2014).http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html
Davidson B.L., McCray Jr. P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011; 12:329-40.
De Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: A progress report on siРНК-based therapeutics. Nat. Rev. Drug Discov. 2007; 6:443-53.
Ebihara H., Takada A., Kobasa D., Jones S., Neumann G., Therian H.S., Bray M., Feldmann H., KawaokaY. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006; 2: e73.
Enterlein S., Warfield K.L., Swenson D.L., Stein D.A., Smith J.L., Gamble C.S., Kroe A.D., Iversen P.L., Bavari S., Muhlberger E. VP 35 knockdown inhibits Ebola virus amplification and protects against a lethal infection in mice. Antimicrob. Agents Chemother. 2006; 50:984-93.
Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849-62.
Geisbert T.W., Hensley L.E., Kagan E. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 2006; 193(12):1650-7.
Geisbert T.W., Larsen T., Geisbert J.B., Paragas J., Young H.A., Frederic T.M., Rote W.E., Vlasuk G.P., Joffe S. Evaluation novel therapies during the Ebola epidemic. Available from: http:// jamanetwork.com/on 28/09/2014 (дата обращения 28.09.2014).http://jamanetwork.com/on
Geisbert T.W., Larsen T., Geisbert J.B., Paragas J., Young H.A., Frederic T.M., Rote W.E., Vlasuk G.P., Joffe S. Evaluation novel therapies during the Ebola epidemic. Available from: http:// jamanetwork.com/on 28/09/2014 (дата обращения 28.09.2014).http://jamanetwork.com/on
Geisbert T.W., Lee A.C.H., Robbins M., Honko A.N., Sood V., Johnson J.C., Jong S., Tavakoli I., Judge A., Hensley L.E., MacLahlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375:1896-905.
Heald A.E., Iversen P.L., Saoud J.B., Sazani P., Charleston J.S., Axtelle T., Wong M., Smith W.B., Vutikullird A., Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg Virus: results of two single ascending dose studies. Available from: http/aac.asm.org/content/58/11/6639.abstract (дата обращения 22.03.2014).
Hensley L.E., Stewens E.L., Yan S.B., Geisbert J.B., Macias W.L., Larsen T., Cassel G.H., Jahrling P.B., Geisbert T.W. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007; 196:390-9.
Hornung V., Guenthner-Biller M., Bourguin С., Ablasser A., Sohlee M., Uemasn S., Noronha A., Manoharan M., Akira S., de Fongerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005; 11:263-70.
Iversen P.L., Warren T.K., Wells J.B., Garza N.L., Mourich D.V., Welch L.S., Panchal R.G., Bavari S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infection. Viruses. 2012; 4:2806-30.
Jahrling P.B., Geisbert J.B., Swearingen J.R., Larsen T., Geisbert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007; 196:400-3.
Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., McLachian I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005; 23:457-62.
Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siРНК therapeutics. Nature materials. 2013; 12:967-77. doi:10.1038/nmat3765..
DOI: 10.1038/nmat3765
Kim D.H., Rossi J.J. Strategies for silencing disease using RNA interference. Nat. Rev. Genet. 2007; 8:173-84.
Maruyama T. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 1999; 73:6024-30.
Prins K.S., Delpeut S., Leung D.W., Reunard O., Volebkova V.A., Reid S.P., Ramanan P., Cardenas W.B., Amarasinghe G.K., Volchov V.E., Basler C.F. Mutations abrogating VP 35 interaction with double stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010; 84:3004-15.
Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Aviles J., Hiatt E., Johnson A., Morton J., Swope K., Bohorov O., Bohorova N., Goodman C., Kim D., Pauly M.H., Velasci J., Pettit J., Olinger G.G., Whaley K., Xu B., Strong J.E., Zetlin L., Kobinger G.P. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53.
Reid S.P., Leung D.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., Volchov V.E., Nichol S.T., Basler C.F. Ebola virus VP24 binds karyopherin alpha 1 and blocks STATi nuclear accumulation. J. Virol. 2006; 80:5156-67.
Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., Mac Lachlan I. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 2008; 19:991-9.
Tam Y.C., Chen S., Cullis P.R. Advances in lipid nanoparticles for siРНК delivery. Pharmaceutics. 2013; 5: 498-507.
Torrecila J., Rodriguez-Gascon A., Solinis M.A., del Pozo-Rodriguez A. Lipid nanoparticles as carriers for RNAi against viral infections current status and future perspectives. Biomed Res. Int. 2014; 2014:161794. doi: 10.1155/2014/161794..
DOI: 10.1155/2014/161794
Volchov V.E., Chepurnov A.A., Volchova V.A., Ternovoj V.A., Klenk H.D. Molecular characterization guinea pig-adapted variants of Ebola virus. Virology. 2000; 277:147-55.
Warfield K.L., Swenson D.L., Olinger G.G., Olinger G.G., Nichols D.K., Pratt W.D., Blonch R., Stein D.A., Aman M.J., Iversen P.L., Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006; 2:e1.
Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8:129-38.
Zhang YunFang, Li DaPeng, Jin Xia, Huang Zhong. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Science China Life Sciences. 2014; 57(10):987-8.